| Literature DB >> 29402314 |
Alia Luz1, Benjarin Santatiwongchai2, Juntana Pattanaphesaj1, Yot Teerawattananon1.
Abstract
BACKGROUND: The use of economic evaluation in healthcare policies and decision-making, which is limited in low- and middle-income countries (LMICs), might be promoted through the improvement of the conduct and reporting of studies. Although the literature indicates that there are many issues affecting the conduct, reporting and use of this evidence, it is unclear which factors should be prioritised in finding solutions. This study aims to identify the top priority issues that impede the conduct, reporting and use of economic evaluation as well as potential solutions as an input for future research topics by the international Decision Support Initiative and other movements.Entities:
Mesh:
Year: 2018 PMID: 29402314 PMCID: PMC5800077 DOI: 10.1186/s12961-018-0280-6
Source DB: PubMed Journal: Health Res Policy Syst ISSN: 1478-4505
Frequency of issues being mentioned in included key publications from PubMed (n = 25)
| Issues | Number of studies in which the issue is mentioned |
|---|---|
| Technical issues | |
| Poor reporting | 9 |
| Perspective not stated | 7 |
| Methodology not presented in a clear and reproducible manner | 2 |
| Disaggregated result not presented | 1 |
| Funding sources not reported | 1 |
| Ethical issues not discussed | 1 |
| Lack of high-quality local clinical data | 7 |
| Lack of local utility data | 4 |
| Sensitivity analysis not properly characterised | 4 |
| Some relevant cost data omitted | 3 |
| Incremental analysis not performed | 3 |
| Clinical data not based on systematic review | 2 |
| Lack of reliable cost data | 2 |
| Discounting not performed, if relevant | 2 |
| Methodology lacks standard, transparent methods | 2 |
| Comparator not appropriate | 1 |
| Variations among costs, effects and cost-effectiveness data within and between settings | 1 |
| No objective budget constraints or threshold applied | 1 |
| No reference case specific to developing contexts | 1 |
| Economic evaluation is not included in a formal process to support decision-making process | 1 |
| Limited local research capacity | 1 |
| Limited local good quality journal with a high standard process of review | 1 |
| Misunderstanding between researchers, academia and policy-makers | 1 |
Issues in selected studies from the Centre for Reviews and Dissemination database (n = 100)
| Issues | Numbers of studies in which the issue is mentioned |
|---|---|
| Poor reporting | 81 |
| Perspective of analysis not stated | 37 |
| Price year not reported | 37 |
| Decision model not described, if relevant | 21 |
| Limited details on utility/disutility data | 15 |
| Source of cost data not provided | 12 |
| Discount rate for cost not provided | 12 |
| Limited details on source of effectiveness data | 11 |
| Limited details on disaggregated cost data | 11 |
| Sources of effectiveness data not provided | 7 |
| Not clear whether all relevant options were included | 5 |
| Details on study population not provided | 5 |
| Justification of the comparator was not provided | 4 |
| The comparator was unclear | 3 |
| Details of comparators were not provided | 2 |
| Unclear whether discounting is performed for effectiveness | 2 |
| Discount rate for effectiveness not provided | 2 |
| Details on intervention is not provided | 1 |
| Unclear whether discounting is performed for cost | 1 |
| Limited details on currency conversion | 1 |
| No specific threshold applied | 78 |
| Incremental analysis not performed | 41 |
| Sensitivity analysis not performed | 31 |
| Health measures used not appropriate | 28 |
| All relevant evidence not included | 17 |
| Discounting of cost not appropriately performed | 16 |
| Sources of effectiveness should be improved | 11 |
| Some relevant costs are omitted | 7 |
| Charges used instead of cost | 4 |
| Sources of cost data should be improved | 3 |
| Discounting of effectiveness not appropriately performed | 2 |
Characteristics of respondents
| Characteristics | Number and percentage of respondents |
|---|---|
| Highest level of education completed ( | |
| Undergraduate | 11 (10%) |
| Masters | 58 (53%) |
| Doctorate | 41 (35%) |
| Economic evaluation as a major part of the respondent study ( | |
| Yes | 70 (64%) |
| No | 40 (36%) |
| Years of experience in the field of economic evaluation ( | |
| 0–5 | 49 (47%) |
| 6–10 | 32 (30%) |
| 11–15 | 8 (8%) |
| 16–20 | 8 (8%) |
| 21–25 | 2 (2%) |
| 26 or more | 5 (5%) |
| Affiliation ( | |
| Academic | 46 (42%) |
| Public health institute | 46 (42%) |
| Governmental research bodies | 7 (6%) |
| Ministry of Health | 7 (6%) |
| Governmental bodies (unspecified) | 4 (4%) |
| Consultancies | 4 (4%) |
| Industries | 4 (4%) |
| Others | 4 (4%) |
| Regions of affiliation ( | |
| Africa | 34 (32%) |
| America | 18 (17%) |
| Eastern Mediterranean | 6 (6%) |
| Europe | 16 (15%) |
| South East Asia | 42 (40%) |
| Western Pacific | 34 (32%) |
Ranked technical issues, presented as groups of related issues and by rank
| Priority rank | Technical issue | Score | Frequency in first rank |
|---|---|---|---|
| Lack of relevant data | |||
| 1 | Lack of high-quality local clinical data, where such data are critical to the decision | 80 | 21% |
| 3 | Insufficient data to conduct study from chosen perspective | 57 | 9% |
| 5 | Absence of locally relevant health state preference data suitable for estimating QALYs or DALYs | 43 | 7% |
| Lack of commonly accepted standard or methods | |||
| 2 | Poor reporting | 67 | 21% |
| 4 | A lack of commonly accepted standards for economic evaluation that is relevant to the LMIC for which the analysis is undertaken | 57 | 19% |
| Inappropriate use of methods | |||
| 6 | Inappropriate choice of comparator(s) | 29 | 7% |
| 7 | No budget constraints or thresholds considered | 26 | 5% |
| 8 | Generalisability not discussed | 14 | 3% |
| 10 | Equity and/or gender implications not considered | 12 | 0% |
| 11 | No incremental analysis | 11 | 1% |
| 12 | No, or inappropriate, sensitivity analysis | 10 | 0% |
| 13 | All impacts implied by the chosen perspective not investigated | 10 | 3% |
| 15 | Time horizon too short to capture relevant costs and health effects | 9 | 1% |
| Inappropriate use of data | |||
| 9 | Clinical data not based on systematic review or primary clinical data not compared with similar studies done elsewhere | 12 | 1% |
| 14 | Uncritical use of charges for cost data | 9 | 1% |
Fig. 1Priority technical issues in different WHO regions. SEA South East Asia region, AFR African region, PAH Pan American region, EUR European region, EMR Eastern Mediterranean region, WPR Western Pacific region
Ranked context-specific issues
| Rank | Context-specific issue | Score | Frequency in first rank |
|---|---|---|---|
| 1 | Economic evaluations not included as a part of the decision-making process | 26 | 39% |
| 2 | Limited local capacity to conduct or contextualise research | 19 | 29% |
| 3 | Lack of funding for the necessary research | 10 | 15%a |
| 4 | Misunderstandings and communications weaknesses between researchers, academia and end-users of the evidence | 10 | 15% |
| 5 | Absence of local journal with a high-quality reviewing processes | 1 | 2% |
aThe rank takes account of frequencies in the regional analysis
Fig. 2Priority context-specific issues in different WHO regions. SEA South East Asia region, AFR African region, PAH Pan American region, EUR European region, EMR Eastern Mediterranean region, WPR Western Pacific region
Solutions proposed by respondent and their frequency of being proposed
| Proposed solution | Frequency |
|---|---|
| Development of tools and standards | |
| Development of standard methodological and reporting guidelines that are acceptable (i.e. understandable and perceived useful) for decision-makers and stakeholders in the country | 19 |
| ᅟImprovement or development of tools for utility weights | 3 |
| Development of standard approaches for costing | 1 |
| Generation of data and construction of databases | |
| Construction of a database to collate all essential data and information needed in the analysis, i.e. cost and clinical data, from data that already exists in the health systems | 7 |
| Generation of cost data through studies or standard cost lists | 2 |
| Development of utility or disutility weights for LMICs locally and/or by region | 2 |
| Conduct of studies on utility weights in the context | 2 |
| Encouragement to the conduct of local clinical studies | 1 |
| Conduct of research to estimate cost-effectiveness threshold | 1 |
| Capacity-building | |
| Capacity-building to increase both the quantity of economic evaluation practitioners and the quality of their work | 7 |
| Networking and system to support and appraise | |
| Create local system, e.g. technical committee, to support and appraise the conduct of economic evaluation | 4 |
| Engagement of relevant stakeholders in the conduct of studies and facilitating more interaction between and among different stakeholders to create buy-in | 3 |
| Creation of linkage and network with other researchers working in developing countries for knowledge and research sharing | 1 |